O	0	5	Joint
O	6	16	Estimation
O	17	19	of
B-condition	20	27	Cardiac
I-condition	28	36	Toxicity
I-condition	37	40	and
I-condition	41	51	Recurrence
I-condition	52	57	Risks
O	58	63	After
O	64	77	Comprehensive
B-intervention	78	83	Nodal
I-intervention	84	90	Photon
O	91	97	Versus
B-control	98	104	Proton
I-control	105	112	Therapy
O	113	116	for
O	117	123	Breast
O	124	130	Cancer
O	130	131	.

O	132	135	The
O	136	141	study
O	142	146	aims
O	147	149	to
O	150	157	perform
O	158	163	joint
O	164	174	estimation
O	175	177	of
O	178	181	the
O	182	186	risk
O	187	189	of
O	190	200	recurrence
O	201	207	caused
O	208	210	by
O	211	221	inadequate
O	222	231	radiation
O	232	236	dose
O	237	245	coverage
O	246	248	of
O	249	254	lymph
O	255	259	node
O	260	267	targets
O	268	271	and
O	272	275	the
O	276	280	risk
O	281	283	of
O	284	291	cardiac
O	292	300	toxicity
O	301	307	caused
O	308	310	by
O	311	320	radiation
O	321	329	exposure
O	330	332	to
O	333	336	the
O	337	342	heart
O	342	343	.

O	344	353	Delivered
O	354	360	photon
O	361	366	plans
O	367	370	are
O	371	379	compared
O	380	384	with
O	385	394	realistic
O	395	401	proton
O	402	407	plans
O	407	408	,
O	409	416	thereby
O	417	426	providing
O	427	435	evidence
O	435	436	-
O	436	441	based
O	442	451	estimates
O	452	454	of
O	455	458	the
O	459	472	heterogeneity
O	473	475	of
O	476	485	treatment
O	486	493	effects
O	494	496	in
O	497	508	consecutive
O	509	514	cases
O	515	518	for
O	519	522	the
O	523	524	2
O	525	534	radiation
O	535	544	treatment
O	545	555	modalities
O	555	556	.

B-total-participants	557	562	Forty
I-total-participants	562	563	-
I-total-participants	563	566	one
O	567	575	patients
O	576	584	referred
O	585	588	for
O	589	603	postlumpectomy
O	604	617	comprehensive
O	618	623	nodal
O	624	630	photon
O	631	642	irradiation
O	643	646	for
O	647	651	left
O	651	652	-
O	652	657	sided
O	658	664	breast
O	665	671	cancer
O	672	676	were
O	677	685	included
O	685	686	.

O	687	698	Comparative
O	699	705	proton
O	706	711	plans
O	712	716	were
O	717	726	optimized
O	727	729	by
O	730	731	a
O	732	736	spot
O	737	745	scanning
O	746	755	technique
O	756	760	with
O	761	767	single
O	767	768	-
O	768	773	field
O	774	786	optimization
O	787	791	from
O	792	793	2
O	794	796	en
O	797	801	face
O	802	807	beams
O	807	808	.

O	809	823	Cardiotoxicity
O	824	828	risk
O	829	832	was
O	833	842	estimated
O	843	847	with
O	848	851	the
O	852	857	model
O	858	860	of
O	861	866	Darby
O	867	869	et
O	870	872	al
O	872	873	,
O	874	877	and
O	878	882	risk
O	883	885	of
O	886	896	recurrence
O	897	906	following
O	907	908	a
O	909	919	compromise
O	920	922	of
O	923	928	lymph
O	929	933	node
O	934	942	coverage
O	943	946	was
O	947	956	estimated
O	957	959	by
O	960	961	a
O	962	968	linear
O	969	973	dose
O	973	974	-
O	974	982	response
O	983	988	model
O	989	995	fitted
O	996	998	to
O	999	1002	the
O	1003	1013	recurrence
O	1014	1018	data
O	1019	1023	from
O	1024	1027	the
O	1028	1036	recently
O	1037	1046	published
O	1047	1052	EORTC
O	1053	1054	(
O	1054	1062	European
O	1063	1075	Organisation
O	1076	1079	for
O	1080	1088	Research
O	1089	1092	and
O	1093	1102	Treatment
O	1103	1105	of
O	1106	1112	Cancer
O	1112	1113	)
O	1114	1119	22922
O	1119	1120	/
O	1120	1125	10925
O	1126	1129	and
O	1130	1134	NCIC
O	1134	1135	-
O	1135	1138	CTG
O	1139	1140	(
O	1140	1148	National
O	1149	1155	Cancer
O	1156	1165	Institute
O	1166	1168	of
O	1169	1175	Canada
O	1176	1184	Clinical
O	1185	1191	Trials
O	1192	1197	Group
O	1197	1198	)
O	1199	1201	MA
O	1201	1202	.
O	1202	1204	20
O	1205	1215	randomized
O	1216	1226	controlled
O	1227	1233	trials
O	1233	1234	.

O	1235	1241	Excess
O	1242	1250	absolute
B-outcome	1251	1255	risk
I-outcome	1256	1258	of
I-outcome	1259	1266	cardiac
I-outcome	1267	1276	morbidity
O	1277	1280	was
O	1281	1286	small
O	1287	1291	with
O	1292	1298	photon
O	1299	1306	therapy
O	1307	1309	at
O	1310	1312	an
O	1313	1321	attained
O	1322	1325	age
O	1326	1328	of
O	1329	1331	80
O	1332	1337	years
O	1337	1338	,
O	1339	1343	with
O	1344	1350	median
O	1351	1357	values
O	1358	1360	of
B-iv-cont-median	1361	1362	1
I-iv-cont-median	1362	1363	.
I-iv-cont-median	1363	1364	0
I-iv-cont-median	1364	1365	%
O	1366	1367	(
O	1367	1372	range
O	1372	1373	,
O	1374	1375	0
O	1375	1376	.
O	1376	1377	2
O	1377	1378	%
O	1378	1379	-
O	1379	1380	2
O	1380	1381	.
O	1381	1382	9
O	1382	1383	%
O	1383	1384	)
O	1385	1388	and
B-iv-cont-median	1389	1390	0
I-iv-cont-median	1390	1391	.
I-iv-cont-median	1391	1392	5
I-iv-cont-median	1392	1393	%
O	1394	1395	(
O	1395	1400	range
O	1400	1401	,
O	1402	1403	0
O	1403	1404	.
O	1404	1406	03
O	1406	1407	%
O	1407	1408	-
O	1408	1409	1
O	1409	1410	.
O	1410	1411	0
O	1411	1412	%
O	1412	1413	)
O	1414	1418	with
O	1419	1422	and
O	1423	1430	without
O	1431	1438	cardiac
O	1439	1443	risk
O	1444	1451	factors
O	1451	1452	,
O	1453	1465	respectively
O	1465	1466	,
O	1467	1470	but
O	1471	1475	even
O	1476	1481	lower
O	1482	1486	with
O	1487	1493	proton
O	1494	1501	therapy
O	1502	1503	(
B-cv-cont-median	1503	1504	0
I-cv-cont-median	1504	1505	.
I-cv-cont-median	1505	1507	13
I-cv-cont-median	1507	1508	%
O	1509	1510	[
O	1510	1515	range
O	1515	1516	,
O	1517	1518	0
O	1518	1519	.
O	1519	1521	02
O	1521	1522	%
O	1522	1523	-
O	1523	1524	0
O	1524	1525	.
O	1525	1526	5
O	1526	1527	%
O	1527	1528	]
O	1529	1532	and
B-iv-cont-median	1533	1534	0
I-iv-cont-median	1534	1535	.
I-iv-cont-median	1535	1537	06
I-iv-cont-median	1537	1538	%
O	1539	1540	[
O	1540	1545	range
O	1545	1546	,
O	1547	1548	0
O	1548	1549	.
O	1549	1552	004
O	1552	1553	%
O	1553	1554	-
O	1554	1555	0
O	1555	1556	.
O	1556	1557	3
O	1557	1558	%
O	1558	1559	]
O	1559	1560	,
O	1561	1573	respectively
O	1573	1574	)
O	1574	1575	.

O	1576	1579	The
O	1580	1586	median
O	1587	1596	estimated
O	1597	1603	excess
O	1604	1612	absolute
B-outcome	1613	1617	risk
I-outcome	1618	1620	of
I-outcome	1621	1627	breast
I-outcome	1628	1634	cancer
I-outcome	1635	1645	recurrence
I-outcome	1646	1651	after
I-outcome	1652	1654	10
I-outcome	1655	1660	years
O	1661	1664	was
B-iv-cont-median	1665	1666	0
I-iv-cont-median	1666	1667	.
I-iv-cont-median	1667	1669	10
I-iv-cont-median	1669	1670	%
O	1671	1672	(
O	1672	1677	range
O	1677	1678	,
O	1679	1680	0
O	1680	1681	.
O	1681	1682	0
O	1682	1683	%
O	1683	1684	-
O	1684	1685	0
O	1685	1686	.
O	1686	1687	9
O	1687	1688	%
O	1688	1689	)
O	1690	1694	with
O	1695	1702	photons
O	1703	1706	and
B-cv-cont-median	1707	1708	0
I-cv-cont-median	1708	1709	.
I-cv-cont-median	1709	1711	02
I-cv-cont-median	1711	1712	%
O	1713	1714	(
O	1714	1719	range
O	1719	1720	,
O	1721	1722	0
O	1722	1723	.
O	1723	1724	0
O	1724	1725	%
O	1725	1726	-
O	1726	1727	0
O	1727	1728	.
O	1728	1730	07
O	1730	1731	%
O	1731	1732	)
O	1733	1737	with
O	1738	1745	protons
O	1745	1746	.

O	1747	1750	The
O	1751	1762	association
O	1763	1770	between
O	1771	1774	age
O	1775	1777	of
O	1778	1781	the
O	1782	1789	patient
O	1790	1793	and
O	1794	1801	benefit
O	1802	1806	from
O	1807	1813	proton
O	1814	1821	therapy
O	1822	1825	was
O	1826	1830	weak
O	1830	1831	,
O	1832	1838	almost
O	1839	1842	non
O	1842	1843	-
O	1843	1851	existing
O	1852	1853	(
O	1853	1861	Spearman
O	1862	1866	rank
O	1867	1879	correlations
O	1880	1882	of
O	1883	1884	-
O	1884	1885	0
O	1885	1886	.
O	1886	1888	15
O	1889	1892	and
O	1893	1894	-
O	1894	1895	0
O	1895	1896	.
O	1896	1898	30
O	1899	1903	with
O	1904	1907	and
O	1908	1915	without
O	1916	1923	cardiac
O	1924	1928	risk
O	1929	1936	factors
O	1936	1937	,
O	1938	1950	respectively
O	1950	1951	)
O	1951	1952	.

O	1953	1959	Modern
O	1960	1966	photon
O	1967	1974	therapy
O	1975	1981	yields
O	1982	1989	limited
B-outcome	1990	1994	risk
I-outcome	1995	1997	of
I-outcome	1998	2005	cardiac
I-outcome	2006	2014	toxicity
O	2015	2017	in
O	2018	2022	most
O	2023	2031	patients
O	2031	2032	,
O	2033	2036	but
O	2037	2043	proton
O	2044	2051	therapy
O	2052	2055	can
O	2056	2062	reduce
O	2063	2066	the
O	2067	2076	predicted
O	2077	2081	risk
O	2082	2084	of
O	2085	2092	cardiac
O	2093	2101	toxicity
O	2102	2104	by
O	2105	2107	up
O	2108	2110	to
B-iv-cont-median	2111	2112	2
I-iv-cont-median	2112	2113	.
I-iv-cont-median	2113	2114	9
I-iv-cont-median	2114	2115	%
O	2116	2119	and
O	2120	2123	the
O	2124	2128	risk
O	2129	2131	of
O	2132	2138	breast
O	2139	2145	cancer
O	2146	2156	recurrence
O	2157	2159	by
B-cv-cont-median	2160	2161	0
I-cv-cont-median	2161	2162	.
I-cv-cont-median	2162	2163	9
I-cv-cont-median	2163	2164	%
O	2165	2167	in
O	2168	2178	individual
O	2179	2187	patients
O	2187	2188	.

O	2189	2198	Predicted
O	2199	2206	benefit
O	2207	2217	correlates
O	2218	2224	weakly
O	2225	2229	with
O	2230	2233	age
O	2233	2234	.

O	2235	2243	Combined
O	2244	2254	assessment
O	2255	2257	of
O	2258	2261	the
O	2262	2266	risk
O	2267	2271	from
O	2272	2279	cardiac
O	2280	2288	exposure
O	2289	2292	and
O	2293	2303	inadequate
O	2304	2310	target
O	2311	2319	coverage
O	2320	2322	is
O	2323	2332	desirable
O	2333	2336	for
O	2337	2345	rational
O	2346	2359	consideration
O	2360	2362	of
O	2363	2372	competing
O	2373	2379	photon
O	2380	2383	and
O	2384	2390	proton
O	2391	2398	therapy
O	2399	2404	plans
O	2404	2405	.
